Post Content
Legend Biotech (NASDAQ:LEGN) is one of the most promising mid-cap healthcare stocks under $50.
As of December 19 closing, the consensus ratings for Legend Biotech (NASDAQ:LEGN) remain bullish. After a drop of almost 33% during 2025, the stock has received coverage from 11 analysts. 10 of them assigned Buy ratings and 1 assigned a Hold call. With no Sell ratings, the stock has an estimated 1-year average price target of $68.20 a share. For investors, there is a massive 211% upside potential from the current trading levels.
Mila Supinskaya Glashchenko/Shutterstock.com
On December 17, Cantor Fitzgerald analyst Eric Schmidt reaffirmed his overweight stance on Legend Biotech (NASDAQ:LEGN). He assigned a Buy rating to the stock with a target price of $74. As per his estimates, the stock offers a massive 238% upside potential at the current trading range.
Schmidt spoke about management’s view of CAR-T cell therapy, Carvykti. Management believes it to be a unique cure for myeloma amid demonstrated survival benefits, backed by data spanning over an extended time horizon. The analyst also highlighted the increasing demand for myeloma treatment and how the management looks at it to scale up their production. According to Schmidt, these factors outweigh any potential competitive threats in the market and provide for a strong investment case.
Legend Biotech (NASDAQ:LEGN) is a commercial-stage biopharmaceutical company that develops innovative therapies. Being an end-to-end cell therapy company, they focus on medication for serious diseases such as hematologic malignancies and solid tumors.
While we acknowledge the potential of LEGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Cathie Wood’s Stock Portfolio: Top 10 Stocks to Buy and 30 Most Fantastic Stocks Every Investor Should Pay Attention To.
Disclosure: None. This article is originally published at Insider Monkey.